https://doi.org/10.4081/hmr.v2i5.749

Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 346
PDF: 411
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A Dreyling
support@pagepress.org
Bendamustine is a rationally designed drug to combine both alkylating and antimetabolite functions with good tolerability. The cytotoxic effects of bendamustine differ from those of other alkylating agents, since in contrast to other alkylating agents, bendamustine activates a base excision DNA repair pathway rather than an alkyltransferase repair mechanism. Gene expression analyses showed that bendamustine has multiple mechanisms of action, including activation of DNA-damage stress responses and apoptosis, inhibition of mitotic checkpoints, and induction of mitotic catastrophe, a necrotic form of cell death that occurs during metaphase and is distinct from apoptosis (Leoni et al, Clin Cancer Res 2008).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Dreyling, A. (2009). Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.749
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).